These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16396052)

  • 1. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
    Nash DT
    J Natl Med Assoc; 2005 Dec; 97(12):1600-7. PubMed ID: 16396052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of the metabolic syndrome.
    Daskalopoulou SS; Mikhailidis DP; Elisaf M
    Angiology; 2004; 55(6):589-612. PubMed ID: 15547646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of C-reactive protein in primary and secondary prevention.
    Corrado E; Novo S
    J Investig Med; 2007 Dec; 55(8):430-8. PubMed ID: 18163969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study.
    Jylhävä J; Haarala A; Eklund C; Pertovaara M; Kähönen M; Hutri-Kähönen N; Levula M; Lehtimäki T; Huupponen R; Jula A; Juonala M; Viikari J; Raitakari O; Hurme M
    J Intern Med; 2009 Sep; 266(3):286-95. PubMed ID: 19702793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.
    Ridker PM
    Circulation; 2003 Sep; 108(12):e81-5. PubMed ID: 14504253
    [No Abstract]   [Full Text] [Related]  

  • 14. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
    Koh KK; Han SH; Quon MJ
    J Am Coll Cardiol; 2005 Dec; 46(11):1978-85. PubMed ID: 16325028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.
    Nambi V; Ballantyne CM
    Curr Atheroscler Rep; 2005 Feb; 7(1):22-8. PubMed ID: 15683598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
    Haffner SM
    Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.